Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
SHANGHAI and HONG KONG, Sept. 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Huawei netinteractieve AIDC-oplossing: Het nieuwe paradigma van AI-infrastructuur vormgeven
- À l'occasion du salon IDEE 2026, Huawei Digital Power présente des solutions adaptées à divers scénarios, intégrant la formation de réseau et l'IA
- Reap Launches First Ever Managed Fraud and Risk Service for Card Programs
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →